Consequences of Discontinuing a 4/6 Cyclin D-Dependent Kinase Inhibitor During Endocrine Treatment in Hormone-Sensitive Metastatic Breast Cancer Patients in the Context of the COVID-19 Outbreak

The impact of some hasty medical decision made during the first wave of the Coronavirus Disease 2019 (COVID-19) remains unknown. We have evaluated the consequences of one of these precautionary measures: the withdrawal of the cyclin D-dependent kinases 4/6 inhibitor (CDK4/6i) in patients whose metas...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Clinical breast cancer Ročník 23; číslo 1; s. 32 - 37
Hlavní autoři:	Martin, Sophie, Pflumio, Carole, Trensz, Philippe, Schaff-Wendling, Frederique, Weindling, Michal Kalish, Fischbach, Cathie, Pierard, Laure, Limacher, Jean-Marc, Nader, Rita, Velten, Michel, Petit, Thierry
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States Elsevier Inc 01.01.2023
Témata:	Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast Neoplasms - pathology CDK4/6 inhibitors COVID-19 Cyclin-Dependent Kinase 4 - antagonists & inhibitors Cyclin-Dependent Kinase 6 - antagonists & inhibitors Disease Progression Female Hepatic metastases Hormones Humans Neoplasm Metastasis Original Study Protein Kinase Inhibitors - administration & dosage Retrospective Studies Treatment withdrawn RR SBR OR OS CI Disease progression ICANS HR HER-2 COVID-19 p LHRH SARS-CoV-2 CDK4/6 inhibitors Hepatic metastases Treatment withdrawn CDK4/6i
ISSN:	1526-8209, 1938-0666, 1938-0666
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!